The LUP might improve IR by acting on prostate cancer, endocrine resistance, advanced glycation end products/receptor for advanced glycation end products (AGE-RAGE) signalling pathway in diabetic complications, proteoglycans in cancer, and kaposi sarcoma-associated herpesvirus infection. Here, RENBP is linked to prostate carcinoma.